Reply to: "HCC prediction post SVR: many tools yet limited generalizability!": De novo HCC risk stratification after HCV cure: All roads lead to Rome?
- PMID: 35868585
- DOI: 10.1016/j.jhep.2022.07.011
Reply to: "HCC prediction post SVR: many tools yet limited generalizability!": De novo HCC risk stratification after HCV cure: All roads lead to Rome?
Conflict of interest statement
Conflict of interest G.S. received travel support from Gilead. E.L.M. received grants from Novartis. M.M. served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, Collective Acumen, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.J Hepatol. 2022 Jul;77(1):128-139. doi: 10.1016/j.jhep.2022.01.023. Epub 2022 Feb 6. J Hepatol. 2022. PMID: 35139400 Free PMC article.
-
HCC prediction post SVR: Many tools yet limited generalizability!J Hepatol. 2022 Oct;77(4):1226-1228. doi: 10.1016/j.jhep.2022.04.028. Epub 2022 May 5. J Hepatol. 2022. PMID: 35526784 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
